Co-Diagnostics, Inc.
Co-Diagnostics, Inc. is listed today as Co-Diagnostics, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2021 | $47 M | Private placement after listing | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Co-Diagnostics, Inc., its revenue in fiscal 2025 came from these product and service lines: Grant $200,000 (33%).
Annual report (SEC XBRL) · Dec 2025
Co-Diagnostics, Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Jan 2022).
SEC Form D (revenue range) · Jan 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2022
Products and services#
No products or services of Co-Diagnostics, Inc. are on record.
Investors#
No investor of Co-Diagnostics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Co-Diagnostics, Inc. shares, as of Sep 30, 2026.
- Vanguard Capital Management LLC$0 M0.55%
- Geode Capital Management, LLC$0 M0.47%
- Private Advisory Group LLC$0 M0.37%
- HRT Financial LP$0 M0.29%
- Citigroup Inc$0 M0.24%
- Jane Street Group, LLC$0 M0.23%
- Vanguard Fiduciary Trust Co$0 M0.19%
- Susquehanna International Group, LLP$0 M0.15%
- State Street Corp$0 M0.14%
- Tower Research Capital LLC (TRC)$0 M0.07%
- Jpmorgan Chase & Co$0 M0.02%
- UBS Group AG$0 M0.01%
- Morgan Stanley$0 M0.01%
- SBI Securities Co., Ltd.$0 M0.00%
- Smartleaf Asset Management LLC$0 M0.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brian Brown | Secretary | Jan 2022 |
| Dwight Egan | Chief Executive Officer | Jan 2022 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.